<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646177</url>
  </required_header>
  <id_info>
    <org_study_id>13685</org_study_id>
    <secondary_id>I1F-MC-RHBC</secondary_id>
    <nct_id>NCT01646177</nct_id>
  </id_info>
  <brief_title>A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)</brief_title>
  <acronym>UNCOVER-3</acronym>
  <official_title>A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to
      etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2012</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">May 22, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]</measure>
    <time_frame>Week 12</time_frame>
    <description>The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Body Surface Area (BSA) Involvement of Psoriasis</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score * 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Severity</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies</measure>
    <time_frame>Week 12</time_frame>
    <description>The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population * 100.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1346</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg etanercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg etanercept</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>50 mg etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg ixekizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 1</arm_group_label>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 2</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presents with chronic plaque psoriasis based on a confirmed diagnosis of chronic
             psoriasis for at least 6 months prior to randomization

          -  At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization

          -  Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and
             Severity Index (PASI) score of at least 12 at screening and at randomization

          -  Candidate for phototherapy and/or systemic therapy

          -  Men must agree to use a reliable method of birth control or remain abstinent during
             the study

          -  Women must agree to use reliable birth control or remain abstinent during the study
             and for at least 12 weeks after stopping treatment

        Exclusion Criteria:

          -  Pustular, erythrodermic, and/or guttate forms of psoriasis

          -  History of drug-induced psoriasis

          -  Prior use of etanercept

          -  Clinically significant flare of psoriasis during the 12 weeks prior to randomization

          -  Concurrent or recent use of any biologic agent

          -  Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens
             and ultraviolet A [PUVA], ultraviolet B [UVB]) within the previous 4 weeks; or had
             topical psoriasis treatment within the previous 2 weeks prior to randomization

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             prior to randomization and during the study

          -  Have participated in any study with interleukin 17 (IL-17) antagonists, including
             ixekizumab

          -  Serious disorder or illness other than plaque psoriasis

          -  Serious infection within the last 3 months

          -  Breastfeeding or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1055AA0</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Autónoma De Buenosaire</city>
        <zip>C1199ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z-3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 0W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ergolding</city>
        <zip>84038</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freiburg</city>
        <zip>79100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Freising</city>
        <zip>85354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiel</city>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Münster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Northeim</city>
        <zip>37154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mako</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oroshaza</city>
        <zip>5900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pecs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krasnodar</city>
        <zip>350020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>195112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>November 1, 2019</verification_date>
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>August 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2016</results_first_posted>
  <disposition_first_submitted>September 29, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 8, 2014</disposition_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study has 4 periods: Period 1 - Screening; Period 2 - Blinded Induction Dosing Period (Weeks 0 to 12); Period 3 - Long-Term Extension Period (Weeks 12 to 264); Period 4 - Post-Treatment Follow-Up Period (Minimum of 12 Weeks)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (PBO) for ixekizumab (Week 0) given as 2 subcutaneous (SC) injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="P2">
          <title>50 mg Etanercept (ETN)</title>
          <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
        </group>
        <group group_id="P3">
          <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
          <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="P4">
          <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
          <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="P5">
          <title>PBO/IXE80Q4W</title>
          <description>Participants who received placebo during the induction period and received 80 mg ixekizumab SC injection every four weeks (IXE80Q4W) in the Long-term extension period.</description>
        </group>
        <group group_id="P6">
          <title>ETN/IXE80Q4W</title>
          <description>Participants who received Etanercept during the induction period and received IXE80Q4W in the long-term extension period.</description>
        </group>
        <group group_id="P7">
          <title>IXE80Q4W/IXE80Q4W</title>
          <description>Participants who received 80 mg ixe Q4W during the induction period and received IXE80Q4W in the long-term extension period.</description>
        </group>
        <group group_id="P8">
          <title>IXE80Q2W/IXE80Q4W</title>
          <description>Participants who received 80 mg ixe Q2W (IXE80Q2W) during the induction period and received IXE80Q4W in the long-term extension period.</description>
        </group>
        <group group_id="P9">
          <title>PBO Follow-Up Period</title>
          <description>Participants who received PBO in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
        <group group_id="P10">
          <title>ETN Follow-Up Period</title>
          <description>Participants who received etanercept (ETN) in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
        <group group_id="P11">
          <title>IXE80Q4W Follow-Up Period</title>
          <description>Participants who received 80 mg ixe Q4W in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
        <group group_id="P12">
          <title>IXE80Q2W Follow-Up Period</title>
          <description>Participants who received 80 mg ixe Q2W in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Blinded Induction Dosing (Week 0-12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="382"/>
                <participants group_id="P3" count="386"/>
                <participants group_id="P4" count="385"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="382"/>
                <participants group_id="P3" count="382"/>
                <participants group_id="P4" count="384"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="369"/>
                <participants group_id="P3" count="360"/>
                <participants group_id="P4" count="363"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-Term Extension Period (Week 12-264)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P2" count="0">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P3" count="0">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P4" count="0">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P5" count="183">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P6" count="369">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P7" count="360">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P8" count="362">Participants completed prior period then proceeded to IXE80Q4W long-term extension period.</participants>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="183"/>
                <participants group_id="P6" count="369"/>
                <participants group_id="P7" count="360"/>
                <participants group_id="P8" count="362"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="135"/>
                <participants group_id="P6" count="256"/>
                <participants group_id="P7" count="244"/>
                <participants group_id="P8" count="255"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="113"/>
                <participants group_id="P7" count="116"/>
                <participants group_id="P8" count="107"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="30"/>
                <participants group_id="P7" count="29"/>
                <participants group_id="P8" count="27"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="18"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Disposition Form</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Period (Minimum of 12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P6" count="0">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P7" count="0">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P8" count="0">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P9" count="157">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P10" count="309">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P11" count="305">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
                <participants group_id="P12" count="313">Participants who completed or discontinued from study treatment and entered the follow-up period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="157"/>
                <participants group_id="P10" count="309"/>
                <participants group_id="P11" count="305"/>
                <participants group_id="P12" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="126"/>
                <participants group_id="P10" count="233"/>
                <participants group_id="P11" count="225"/>
                <participants group_id="P12" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="31"/>
                <participants group_id="P10" count="76"/>
                <participants group_id="P11" count="80"/>
                <participants group_id="P12" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="28"/>
                <participants group_id="P11" count="34"/>
                <participants group_id="P12" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="21"/>
                <participants group_id="P11" count="19"/>
                <participants group_id="P12" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="B2">
          <title>50 mg Etanercept</title>
          <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12. Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
        </group>
        <group group_id="B3">
          <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
          <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10.
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="B4">
          <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
          <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
            <count group_id="B2" value="382"/>
            <count group_id="B3" value="386"/>
            <count group_id="B4" value="385"/>
            <count group_id="B5" value="1346"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="358"/>
                    <measurement group_id="B4" value="351"/>
                    <measurement group_id="B5" value="1238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="428"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="258"/>
                    <measurement group_id="B4" value="254"/>
                    <measurement group_id="B5" value="918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="269"/>
                    <measurement group_id="B4" value="259"/>
                    <measurement group_id="B5" value="924"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="360"/>
                    <measurement group_id="B4" value="361"/>
                    <measurement group_id="B5" value="1248"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)</title>
        <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12. Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)</title>
          <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.</description>
          <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="291"/>
                    <measurement group_id="O4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12. Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.</description>
          <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="204"/>
                    <measurement group_id="O3" value="325"/>
                    <measurement group_id="O4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)</title>
        <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)</title>
          <description>The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.</description>
          <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.</description>
          <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="252"/>
                    <measurement group_id="O4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</title>
        <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)</title>
          <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.</description>
          <population>All randomized participants. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the Non-Responder Imputation (NRI) analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="386"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]</title>
        <description>The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants and had an Itch NRS score &gt;=4 at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]</title>
          <description>The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.</description>
          <population>All randomized participants and had an Itch NRS score &gt;=4 at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="200"/>
                    <measurement group_id="O3" value="250"/>
                    <measurement group_id="O4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</title>
        <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants and had at least one post-dose measurement of DLQI.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</title>
          <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants and had at least one post-dose measurement of DLQI.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="375"/>
                <count group_id="O4" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.32"/>
                    <measurement group_id="O2" value="-8.0" spread="0.23"/>
                    <measurement group_id="O3" value="-9.6" spread="0.23"/>
                    <measurement group_id="O4" value="-10.2" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score</title>
        <description>The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants and had fingernail involvement at baseline and had at least one post-dose measurement of NAPSI.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score</title>
          <description>The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants and had fingernail involvement at baseline and had at least one post-dose measurement of NAPSI.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="226"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6362" spread="1.0991"/>
                    <measurement group_id="O2" value="-6.4015" spread="0.7716"/>
                    <measurement group_id="O3" value="-9.9793" spread="0.7838"/>
                    <measurement group_id="O4" value="-10.4145" spread="0.7820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Body Surface Area (BSA) Involvement of Psoriasis</title>
        <description>Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants and had at least one post-dose measurement of BSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Body Surface Area (BSA) Involvement of Psoriasis</title>
          <description>Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants and had at least one post-dose measurement of BSA.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="377"/>
                <count group_id="O4" value="380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.03"/>
                    <measurement group_id="O2" value="-16.4" spread="0.73"/>
                    <measurement group_id="O3" value="-23.2" spread="0.73"/>
                    <measurement group_id="O4" value="-23.2" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score</title>
        <description>PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants and had scalp psoriasis at baseline and had at least one post-dose measurement of PSSI.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score</title>
          <description>PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants and had scalp psoriasis at baseline and had at least one post-dose measurement of PSSI.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="345"/>
                <count group_id="O3" value="344"/>
                <count group_id="O4" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="0.53"/>
                    <measurement group_id="O2" value="-15.9" spread="0.38"/>
                    <measurement group_id="O3" value="-18.2" spread="0.38"/>
                    <measurement group_id="O4" value="-18.8" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]</title>
        <description>The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants and had at least one post-dose measurement of QIDS-SR16. Participants with missing QIDS-SR16 data were imputed by Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]</title>
          <description>The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.</description>
          <population>All randomized participants and had at least one post-dose measurement of QIDS-SR16. Participants with missing QIDS-SR16 data were imputed by Last Observation Carried Forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="373"/>
                <count group_id="O4" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.20"/>
                    <measurement group_id="O2" value="-0.5" spread="0.14"/>
                    <measurement group_id="O3" value="-0.9" spread="0.14"/>
                    <measurement group_id="O4" value="-1.3" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.473</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</title>
        <description>The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score * 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants, even if the participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol, and had at least one post-dose measurement of WPAI-PSO. Participants with missing WPAI-PSO data were imputed by Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</title>
          <description>The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score * 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.</description>
          <population>All randomized participants, even if the participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol, and had at least one post-dose measurement of WPAI-PSO. Participants with missing WPAI-PSO data were imputed by Last Observation Carried Forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="375"/>
                <count group_id="O4" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="230"/>
                    <count group_id="O4" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.82"/>
                    <measurement group_id="O2" value="-2.8" spread="0.62"/>
                    <measurement group_id="O3" value="-2.0" spread="0.60"/>
                    <measurement group_id="O4" value="-2.5" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="376"/>
                    <count group_id="O3" value="375"/>
                    <count group_id="O4" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.30"/>
                    <measurement group_id="O2" value="-21.1" spread="0.91"/>
                    <measurement group_id="O3" value="-23.3" spread="0.92"/>
                    <measurement group_id="O4" value="-24.5" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="243"/>
                    <count group_id="O3" value="256"/>
                    <count group_id="O4" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.37"/>
                    <measurement group_id="O2" value="-16.4" spread="1.04"/>
                    <measurement group_id="O3" value="-16.0" spread="1.01"/>
                    <measurement group_id="O4" value="-18.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productively Loss Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="228"/>
                    <count group_id="O4" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.59"/>
                    <measurement group_id="O2" value="-17.4" spread="1.20"/>
                    <measurement group_id="O3" value="-16.7" spread="1.16"/>
                    <measurement group_id="O4" value="-19.3" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Absenteeism Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Absenteeism Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Absenteeism Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Activity Impairment Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Activity Impairment Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Activity Impairment Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Presenteeism Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Presenteeism Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Presenteeism Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Work Productively Loss Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Work Productively Loss Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from Work Productively Loss Score.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
        <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants and had at least one post-dose measurement of SF-36. Participants with missing SF-36 data were imputed by Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
          <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.</description>
          <population>All randomized participants and had at least one post-dose measurement of SF-36. Participants with missing SF-36 data were imputed by Last Observation Carried Forward (LOCF) method.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="362"/>
                <count group_id="O4" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1993" spread="0.5077"/>
                    <measurement group_id="O2" value="3.1176" spread="0.3568"/>
                    <measurement group_id="O3" value="4.1143" spread="0.3587"/>
                    <measurement group_id="O4" value="3.9620" spread="0.3604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1305" spread="0.5768"/>
                    <measurement group_id="O2" value="2.6486" spread="0.4047"/>
                    <measurement group_id="O3" value="3.7961" spread="0.4074"/>
                    <measurement group_id="O4" value="4.2772" spread="0.4093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from PCS.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from PCS.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from PCS.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from MCS.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from MCS.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Includes analysis only from MCS.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Severity</title>
        <description>The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants and had at least one post-dose measurement of Patient's Global Assessment of Disease Severity.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Severity</title>
          <description>The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants and had at least one post-dose measurement of Patient's Global Assessment of Disease Severity.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="377"/>
                <count group_id="O3" value="375"/>
                <count group_id="O4" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.08"/>
                    <measurement group_id="O2" value="-2.3" spread="0.06"/>
                    <measurement group_id="O3" value="-3.1" spread="0.06"/>
                    <measurement group_id="O4" value="-3.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement</title>
        <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants and had a diagnosis of palmoplantar psoriasis at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement</title>
          <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.</description>
          <population>All randomized participants and had a diagnosis of palmoplantar psoriasis at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement</title>
        <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants and had a diagnosis of palmoplantar psoriasis at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement</title>
          <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.</description>
          <population>All randomized participants and had a diagnosis of palmoplantar psoriasis at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement</title>
        <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants and had a diagnosis of palmoplantar psoriasis at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement</title>
          <description>Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.</description>
          <population>All randomized participants and had a diagnosis of palmoplantar psoriasis at baseline. Participants who did not meet clinical response criteria or have missing data at Week 12 will be considered non-responders for the NRI analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies</title>
        <description>The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population * 100.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least one dose of study treatment and had evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ixekizumab (Week 0) given as 2 SC injections followed by placebo for ixekizumab Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept</title>
            <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12.
Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10. Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
            <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies</title>
          <description>The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population * 100.</description>
          <population>All randomized participants who received at least one dose of study treatment and had evaluable data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="378"/>
                <count group_id="O4" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 288 Weeks</time_frame>
      <desc>All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 (Q2W) until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2 (Q4W).</description>
        </group>
        <group group_id="E2">
          <title>50 mg Etanercept</title>
          <description>Etanercept 50 mg (1 SC injection) given twice weekly (every 3-4 days) starting at Week 0 and up to Week 12. Placebo for ixekizumab given as 2 SC injections (Week 0) followed by placebo for ixekizumab Q2W given as 1 SC injection (Weeks 2, 4, 6, 8, and 10).</description>
        </group>
        <group group_id="E3">
          <title>80 mg Ixekizumab Dosing Regimen 2 (Q4W)</title>
          <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q4W (Weeks 4 and 8). Placebo for ixekizumab given as 1 SC injection at Weeks 2, 6, and 10.
Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="E4">
          <title>80 mg Ixekizumab Dosing Regimen 1 (Q2W)</title>
          <description>A starting dose of 160 mg (Week 0) given as 2 SC injections followed by 80 mg given as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10). Placebo for etanercept (1 SC injection) given twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="E5">
          <title>PBO/IXE80Q4W Long-Term Extension</title>
          <description>Participants who received placebo during the induction period and received 80 mg ixekizumab SC injection every four weeks (IXE80Q4W) in the Long-term extension period.</description>
        </group>
        <group group_id="E6">
          <title>ETN/IXE80Q4W Long-Term Extension</title>
          <description>Participants who received Etanercept during the induction period and received IXE80Q4W in the long-term extension period.</description>
        </group>
        <group group_id="E7">
          <title>IXE80Q4W/IXE80Q4W Long-Term Extension</title>
          <description>Participants who received 80 mg ixe Q4W during the induction period and received IXE80Q4W in the long-term extension period.</description>
        </group>
        <group group_id="E8">
          <title>IXE80Q2W/IXE80Q4W Long-Term Extension</title>
          <description>Participants who received 80 mg ixe Q2W (IXE80Q2W) during the induction period and received IXE80Q4W in the long-term extension period.</description>
        </group>
        <group group_id="E9">
          <title>PBO Follow-Up Period</title>
          <description>Participants who received PBO in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
        <group group_id="E10">
          <title>ETN Follow-Up Period</title>
          <description>Participants who received ETN in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
        <group group_id="E11">
          <title>IXE80Q4W Follow-Up</title>
          <description>Participants who received 80 mg ixe Q4W in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
        <group group_id="E12">
          <title>IXE80Q2W Follow-Up</title>
          <description>Participants who received 80 mg ixe Q2W in the Induction Period and entered the Post-Treatment Follow-up Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="384"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="71" subjects_at_risk="369"/>
                <counts group_id="E7" subjects_affected="82" subjects_at_risk="360"/>
                <counts group_id="E8" subjects_affected="55" subjects_at_risk="362"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="11" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diverticulum oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="4" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastroenteritis escherichia coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Spinal cord abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Carotid artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chemical burn of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyperinsulinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vitamin b12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="11" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="8" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="360"/>
                <counts group_id="E8" events="7" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the duodenum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ewing's sarcoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease mixed cellularity stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage ii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Synovial sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Vulval cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Miller fisher syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Polyhydramnios</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bipolar i disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Uterine scar</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Palmoplantar keratoderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Fracture treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Implantable cardiac monitor insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Perineal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="382"/>
                <counts group_id="E4" subjects_affected="123" subjects_at_risk="384"/>
                <counts group_id="E5" subjects_affected="117" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="240" subjects_at_risk="369"/>
                <counts group_id="E7" subjects_affected="236" subjects_at_risk="360"/>
                <counts group_id="E8" subjects_affected="249" subjects_at_risk="362"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="309"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="305"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="384"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E6" events="29" subjects_affected="27" subjects_at_risk="369"/>
                <counts group_id="E7" events="18" subjects_affected="14" subjects_at_risk="360"/>
                <counts group_id="E8" events="32" subjects_affected="25" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="21" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" events="207" subjects_affected="42" subjects_at_risk="382"/>
                <counts group_id="E3" events="99" subjects_affected="43" subjects_at_risk="382"/>
                <counts group_id="E4" events="111" subjects_affected="37" subjects_at_risk="384"/>
                <counts group_id="E5" events="102" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E6" events="186" subjects_affected="24" subjects_at_risk="369"/>
                <counts group_id="E7" events="291" subjects_affected="34" subjects_at_risk="360"/>
                <counts group_id="E8" events="169" subjects_affected="24" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="382"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="384"/>
                <counts group_id="E5" events="24" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E6" events="23" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E7" events="32" subjects_affected="24" subjects_at_risk="360"/>
                <counts group_id="E8" events="47" subjects_affected="36" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E5" events="16" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E8" events="18" subjects_affected="18" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="384"/>
                <counts group_id="E5" events="16" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E6" events="20" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E7" events="23" subjects_affected="21" subjects_at_risk="360"/>
                <counts group_id="E8" events="21" subjects_affected="20" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="382"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="382"/>
                <counts group_id="E4" events="31" subjects_affected="26" subjects_at_risk="384"/>
                <counts group_id="E5" events="124" subjects_affected="55" subjects_at_risk="183"/>
                <counts group_id="E6" events="196" subjects_affected="104" subjects_at_risk="369"/>
                <counts group_id="E7" events="239" subjects_affected="107" subjects_at_risk="360"/>
                <counts group_id="E8" events="222" subjects_affected="112" subjects_at_risk="362"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="305"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="382"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E6" events="26" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E7" events="20" subjects_affected="17" subjects_at_risk="360"/>
                <counts group_id="E8" events="23" subjects_affected="21" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E5" events="22" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E7" events="41" subjects_affected="28" subjects_at_risk="360"/>
                <counts group_id="E8" events="47" subjects_affected="27" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="384"/>
                <counts group_id="E5" events="27" subjects_affected="21" subjects_at_risk="183"/>
                <counts group_id="E6" events="58" subjects_affected="33" subjects_at_risk="369"/>
                <counts group_id="E7" events="67" subjects_affected="48" subjects_at_risk="360"/>
                <counts group_id="E8" events="68" subjects_affected="42" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="384"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E6" events="26" subjects_affected="18" subjects_at_risk="369"/>
                <counts group_id="E7" events="25" subjects_affected="21" subjects_at_risk="360"/>
                <counts group_id="E8" events="39" subjects_affected="21" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E7" events="13" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="382"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="384"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E6" events="24" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E7" events="38" subjects_affected="29" subjects_at_risk="360"/>
                <counts group_id="E8" events="60" subjects_affected="41" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="384"/>
                <counts group_id="E5" events="19" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E6" events="32" subjects_affected="28" subjects_at_risk="369"/>
                <counts group_id="E7" events="33" subjects_affected="23" subjects_at_risk="360"/>
                <counts group_id="E8" events="34" subjects_affected="30" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="382"/>
                <counts group_id="E3" events="23" subjects_affected="16" subjects_at_risk="382"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="384"/>
                <counts group_id="E5" events="15" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E6" events="47" subjects_affected="30" subjects_at_risk="369"/>
                <counts group_id="E7" events="27" subjects_affected="23" subjects_at_risk="360"/>
                <counts group_id="E8" events="39" subjects_affected="27" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="382"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="384"/>
                <counts group_id="E5" events="17" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E6" events="29" subjects_affected="23" subjects_at_risk="369"/>
                <counts group_id="E7" events="18" subjects_affected="14" subjects_at_risk="360"/>
                <counts group_id="E8" events="29" subjects_affected="26" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="384"/>
                <counts group_id="E5" events="16" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E6" events="16" subjects_affected="16" subjects_at_risk="369"/>
                <counts group_id="E7" events="18" subjects_affected="14" subjects_at_risk="360"/>
                <counts group_id="E8" events="20" subjects_affected="16" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="382"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="382"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="384"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" events="25" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E7" events="22" subjects_affected="17" subjects_at_risk="360"/>
                <counts group_id="E8" events="10" subjects_affected="10" subjects_at_risk="362"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="382"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="384"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E6" events="22" subjects_affected="17" subjects_at_risk="369"/>
                <counts group_id="E7" events="28" subjects_affected="17" subjects_at_risk="360"/>
                <counts group_id="E8" events="17" subjects_affected="15" subjects_at_risk="362"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E10" events="10" subjects_affected="10" subjects_at_risk="309"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="384"/>
                <counts group_id="E5" events="24" subjects_affected="20" subjects_at_risk="183"/>
                <counts group_id="E6" events="42" subjects_affected="30" subjects_at_risk="369"/>
                <counts group_id="E7" events="31" subjects_affected="30" subjects_at_risk="360"/>
                <counts group_id="E8" events="31" subjects_affected="26" subjects_at_risk="362"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

